They did have an $8 billion + settlement, but I have heard that this will be whittled down to less than $500 million based on bankruptcy claims and other legal maneuvers that the wealthy can use in our legal system.
Dual punishment types for the population.
Common man punishments vs corporate man punishment.
Huh, I'm not surprised at the slightest
I think they made a documentary about that guy on Netflix, no? It was pretty good. Lost his son to the drugs, IIRC.For the sake of fairness, it was a Jewish pharmacist who exposed the entire opioid plot to begin with. Dan Schneider in Louisiana (and the “Doctor” responsible for that epidemic was black, not Jewish). Overall the parallel legal system theory seems to be true though.
The problem isn't the individual Jewish exception who may be completely independent thinkers. I don't view individual Jews any different than any other person i'd randomly meet. At least the ones who don't display aspects of their ethnocentric/tribal particularisms inadvertently. The problem is when the tribe starts to ascend into the driver's seat of a civilization or culture and slowly just takes over all aspects of society and hollows it out from the inside through exploiting the goyim.For the sake of fairness, it was a Jewish pharmacist who exposed the entire opioid plot to begin with. Dan Schneider in Louisiana (and the “Doctor” responsible for that epidemic was black, not Jewish). Overall the parallel legal system theory seems to be true though.
You will lend money to many nations but will never need to borrow. ... Also, you will rule over many nations, but they will not rule over you.
For the sake of fairness, it was a Jewish pharmacist who exposed the entire opioid plot to begin with. Dan Schneider in Louisiana (and the “Doctor” responsible for that epidemic was black, not Jewish). Overall the parallel legal system theory seems to be true though.
McKinsey Proposed Paying Pharmacy Companies Rebates for OxyContin OverdosesCourt filings reveal consultants’ talk of a records purge during the opioid crisis, and shed new light on sales advice given to the billionaire Sackler family and their drug company, Purdue Pharma.
In a 2017 presentation, according to the records, which were filed in court on behalf of multiple state attorneys general, McKinsey laid out several options to shore up sales. One was to give Purdue’s distributors a rebate for every OxyContin overdose attributable to pills they sold.
Though McKinsey has not been charged by the federal government or sued, it began to worry about legal repercussions in 2018, according to the documents. After Massachusetts filed a lawsuit against Purdue, Martin Elling, a leader for McKinsey’s North American pharmaceutical practice, wrote to another senior partner, Arnab Ghatak: “It probably makes sense to have a quick conversation with the risk committee to see if we should be doing anything” other than “eliminating all our documents and emails. Suspect not but as things get tougher there someone might turn to us.”
The two men were among the highest-ranking consultants at McKinsey. Five years earlier, the documents show, they emailed colleagues about a meeting in which McKinsey persuaded the Sacklers to aggressively market OxyContin.
McKinsey’s involvement in the opioid crisis came to light early last year, with the release of documents from Massachusetts, which is among the states suing Purdue. Those records show that McKinsey was helping Purdue find a way “to counter the emotional messages from mothers with teenagers that overdosed” from OxyContin.
The documents released last week detail McKinsey’s work with Purdue going back to 2008, the year after the drugmaker pleaded guilty to misleading regulators. The Food and Drug Administration had previously told Purdue that OxyContin would face sales restrictions and that doctors prescribing it would require specialized training.
The Sackler family saw those rules as a threat and, joining with McKinsey, made a plan to “band together” with other opioid makers to push back, according to one email. McKinsey prepped Purdue executives for a vital meeting before an F.D.A. advisory committee reviewing its proposed reformulation of OxyContin to make it less prone to abuse. The reformulation went on the market in 2010.
Purdue’s F.D.A. meeting appeared to be at least partly successful. “Even to this day, the F.D.A. has never required specialized training for OxyContin prescribers,” wrote the state lawyers who filed the documents last week.